

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

19 March 2013

Exiqon launches LNA™ gapmers for inhibition of mRNA and lncRNA in functional studies

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression analysis products, today announced the launch of its LNA™ longRNA GapmeR products for specific and efficient inhibition of mRNA and lncRNA.

The LNA™ longRNA GapmeRs are high affinity antisense oligonucleotides used for functional analysis, allowing researchers to study the gene function and downstream biological consequences of silencing a specific mRNA or long non-coding RNA (lncRNA) in cell-cultures or animal models. The broad range of LNA™ longRNA GapmeR products enables researcher to start from initial cost-effective in vitro screening in cell-lines of multiple gapmer designs and continue with high-purity animal-grade gapmers for in vivo testing.

The use of LNA™ enhanced antisense oligonucleotides in functional studies ensures superior performance and higher success rate through increased target accessibility, specificity, binding affinity, and tolerance. In addition, the LNA™ longRNA GapmeRs enable easy unassisted (gymnotic) delivery into the cells resulting in broader applicability including hard-to-transfect cells lines. By use of single-stranded RNase H-activating gapmer designs even targets in the nucleus can be addressed which may not be possible with alternative methods.

“We are thrilled to offer the LNA™ longRNA GapmeR products to our customers. The product line has already been tested by certain early access customer who clearly demonstrated the scientific potential of this product offering.” said Senior Vice President Sales & Marketing, Dr. Henrik M. Pfundheller.

All the LNA™ longRNA GapmeR are designed using Exiqon’s advanced and proprietary bioinformatics design algorithm which in combination with the LNA™ technology secure gapmers with excellent pharmacokinetic and pharmacodynamics properties including high stability and low toxicity for in vivo testing. The incorporation of LNA™ increases the bio-stability which secures the biological activity over an extended period of time.


Exiqon offers a range of compatible LNA™ enhanced products for mRNA and lncRNA research including products for qPCR and in situ hybridization analysis.

Information about the LNA™ longRNA GapmeRs is available here: <http://www.exiqon.com/gapmers>

Additional information

Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)

Henrik M. Pfundheller, Senior Vice President Sales & Marketing, tel. +45 4565 0420
(cell: +45 4090 2106)



About Exiqon

Exiqon's products are based on the proprietary LNA™ technology. This technology offers unique advantages for detection of miRNA biomarkers for life science researchers, drug developers and cancer treating physicians working towards personalizing medicine. Exiqon operates in two business areas: Exiqon Life Sciences has established a position for itself as one of the market's leading providers of miRNA research products for miRNA analysis in cells and body fluids. Our research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Life Sciences is also collaborating with pharmaceutical companies in their effort to target new medicines based on miRNA as biological markers. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases which can help physicians make treatment decisions. Exiqon is listed on the NASDAQ OMX in Copenhagen. For more information about us, please visit www.exiqon.com.

